Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients

[1]  C. Contag,et al.  Adoptive Immunotherapy of Experimental Autoimmune Encephalomyelitis Via T Cell Delivery of the IL-12 p40 Subunit1 , 2001, The Journal of Immunology.

[2]  C. Stratton,et al.  Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[3]  V. Tuohy,et al.  Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[4]  Xin Wang,et al.  IFN-β-1b Inhibits IL-12 Production in Peripheral Blood Mononuclear Cells in an IL-10-Dependent Mechanism: Relevance to IFN-β-1b Therapeutic Effects in Multiple Sclerosis1 , 2000, The Journal of Immunology.

[5]  A. Komiyama,et al.  Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing–remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide , 2000, Journal of Neuroimmunology.

[6]  K. Kunze,et al.  Interleukin‐12 is detectable in sera of patients with multiple sclerosis — association with chronic progressive disease course? , 1999, European journal of neurology.

[7]  F. Barkhof,et al.  Decreased interleukin‐10 and increased interleukin‐12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis , 1999, Annals of neurology.

[8]  M. Hennerici,et al.  Increased release of interleukin-12p40 in MS , 1998, Neurology.

[9]  H. Weiner,et al.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. , 1998, The Journal of clinical investigation.

[10]  J. Drulovic,et al.  Serum interleukin-12 levels in patients with multiple sclerosis , 1998, Neuroscience Letters.

[11]  S. Cook,et al.  Impaired interleukin-12 production in multiple sclerosis patients , 1998, Multiple sclerosis.

[12]  M. Clerici,et al.  Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. , 1998, Journal of immunology.

[13]  G. McDonnell,et al.  Application of the poser criteria in primary progressive multiple sclerosis , 1997, Annals of neurology.

[14]  J. Leonard,et al.  Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. , 1997, The American journal of pathology.

[15]  A J Thompson,et al.  PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS , 1997 .

[16]  F. Nicoletti,et al.  Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis , 1996, Journal of Neuroimmunology.

[17]  D. Hafler,et al.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.

[18]  Susanne A. Fischer,et al.  The interleukin‐12 subunit p40 specifically inhibits effects of the interleukin‐12 heterodimer , 1993, European journal of immunology.

[19]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[20]  D. McFarlin,et al.  Recurrent experimental allergic encephalomyelitis in the Lewis rat. , 1974, Journal of immunology.